A pilot 2-way crossover pharmacokinetic (PK) study (Part A) followedby a pivotal 2-way crossover PK study to assess bioequivalence (Part B) between a test and reference intravenous formulations of 150 mg Fosaprepitant in healthy volunteers
Latest Information Update: 24 Sep 2019
At a glance
- Drugs Fosaprepitant (Primary) ; Fosaprepitant
- Indications Chemotherapy-induced nausea and vomiting
- Focus Pharmacokinetics
- Acronyms CP-NVK016-0001
- Sponsors Nevakar
Most Recent Events
- 23 Sep 2019 Status changed from recruiting to discontinued.
- 19 Jun 2019 New trial record
- 17 Jun 2019 Status changed from not yet recruiting to recruiting according to Australian New Zealand Clinical Trial Registry.